Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2022 Financial Results on May 12, 2022
04/20/2022 - 07:30 AM
RADNOR, Pa. --(BUSINESS WIRE)--
Marinus Pharmaceuticals, Inc. March 31, 2022 after the market closes on May 12, 2022 . The Company will host a conference call at 4:00 p.m. ET on May 12, 2022 to provide a business update and discuss the financial results.
Thursday, May 12 : 4:00 p.m. Eastern Time
About Marinus Pharmaceuticals
Marinus is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a neuroactive steroid GABAA receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. It is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. For more information visit www.marinuspharma.com .
View source version on businesswire.com : https://www.businesswire.com/news/home/20220420005372/en/
Sasha Damouni Ellis
Marinus Pharmaceuticals, Inc.
sdamouni@marinuspharma.com
Source: Marinus Pharmaceuticals
Marinus Pharmaceuticals Inc
MRNS Rankings
#1099 Ranked by Stock Gains
MRNS Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing
About MRNS
marinus pharmaceuticals is a clinical stage biopharmaceutical company dedicated to positively impacting the well-being of patients who suffer from epilepsy and neuropsychiatric disorders. the company is in the midst of developing and commercializing ganaxolone which will treat adults and children with epileptic seizures and women with postpartum depression. on june 29, 2017, the company announced that the u.s. food and drug administration (fda) granted orphan drug designation to ganaxolone for the treatment of cdkl5 disorder. cdkl5 disorder is a severe, rare genetic disorder that affects children at an early age and causes difficult-to-control seizures and neuro-developmental impairment. currently, there are no approved therapies for children with cdkl5 disorder. orphan drug designation is granted by the fda office of orphan products development to novel drugs or biologics that treat a rare disease or condition affecting fewer than 200,000 patients in the u.s. the designation provides
